Skip to main content
SpringerLink
Log in

Iperprolattinemia, farmaci dopaminergici e valvulopatie: vero o falso?

Proposto da Annamaria Colao

  • Published:
L’Endocrinologo Aims and scope

Riassunto

Idopamino-agonisti (DA), specialmente cabergolina (CAB) e bromocriptina (BRC), rappresentano la terapia di prima linea dei prolattinomi. In particolare, CAB è in grado di normalizzare i valori di prolattina e di indurre riduzione del volume tumorale nella grande maggioranza dei pazienti. Evidenze riportate in letteratura hanno sottolineato l’esistenza di una possibile associazione tra l’uso dei DA e lo sviluppo di fibrosi valvolare cardiaca nei pazienti affetti da malattia di Parkinson, mentre nei pazienti affetti da prolattinoma non esistono sufficienti evidenze di una chiara associazione tra prevalenza e/o gravità di valvulopatia e terapia con CAB. È, comunque, raccomandabile un adeguato follow-up cardiologico dei pazienti con prolattinoma che assumono CAB mediante valutazione ecocardiografica annuale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Colao A, Lombardi G 1998 Growth-hormone and prolactin excess. Lancet 352:1455–1461.

    Article  PubMed  CAS  Google Scholar 

  2. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D 2004 Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183.

    Article  PubMed  CAS  Google Scholar 

  3. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38.

    Article  PubMed  CAS  Google Scholar 

  4. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46.

    Article  PubMed  CAS  Google Scholar 

  5. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D’Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777–3784.

    Article  PubMed  CAS  Google Scholar 

  6. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E 2008 Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract 62:1864–1869.

    Article  PubMed  CAS  Google Scholar 

  7. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM 2008 Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348–3356.

    Article  PubMed  CAS  Google Scholar 

  8. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL 2008 Low dose of cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11–R14.

    Article  PubMed  CAS  Google Scholar 

  9. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A 2008 Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1–5.

    Article  PubMed  CAS  Google Scholar 

  10. Devin JK, Lakhani VT, Byrd 3rd BF, Blevins Jr LS 2008 Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 14:672–677.

    Article  PubMed  Google Scholar 

  11. Nachtigall L, Valassi E, Lo J, McCarty D, Passeri J, Utz A, Biller BMK, Miller KK, Klibanski A 2010 Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 72:53–58.

    Article  CAS  Google Scholar 

  12. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA 2009 Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104–108.

    Article  Google Scholar 

  13. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O 2009 Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153–157.

    Article  PubMed  CAS  Google Scholar 

  14. Delgado V, Biermasz NR, van Thiel SW, Hooi Ewe S, Ajmone Marsan N, Holman ER, Feelders RA, Smit JWA, Bax JJ, Pereira AM 2011 Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol, Dec 23, Accepted Article, doi: 10.1111/j.1365-2265.2011.04326.x.

  15. Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, Santos AE, Batista E, Garcia-Pavia P, Sitges M, Mirelis JG, Lucas T, Puig-Domingo M 2012 No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf), doi: 10.1111/j.1365-2265.2012.04349.x. [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università degli Studi di Napoli “Federico II”, Via S. Pansini 5, 80131, Napoli, Italia

    Annamaria Colao & Renata Simona Auriemma

Authors
  1. Annamaria Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renata Simona Auriemma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annamaria Colao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colao, A., Auriemma, R.S. Iperprolattinemia, farmaci dopaminergici e valvulopatie: vero o falso?. L’Endocrinologo 13, 127–131 (2012). https://doi.org/10.1007/BF03345965

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03345965

Search

Navigation